Tande­mAI rais­es $35M in Se­ries A for small mol­e­cule dis­cov­ery, wet labs

Tande­mAI, a small mol­e­cule- and pre­clin­i­cal-fo­cused tech­nol­o­gy com­pa­ny, raised $35 mil­lion in a Se­ries A round of fi­nanc­ing a lit­tle over a year af­ter rais­ing an ini­tial $25 mil­lion to get start­ed.

CEO Jeff He says the com­pa­ny of­fers a three-in-one ap­proach for biotech and phar­ma com­pa­nies: a drug dis­cov­ery plat­form of small mol­e­cules, Chi­na-based wet labs, and ex­perts across var­i­ous fields in­clud­ing chem­istry and AI, all of whom work with clients to bring a drug can­di­date out of the pre­clin­i­cal stage.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER